Lytix Biopharma Competitors and Similar CompaniesClear all

Lytix Biopharma's competitors and similar companies include BioInvent, Inventiva, Therapeia and Calviri.

	Lytix Biopharma Lytix Biopharma is a biotech company developing cancer immunotherapies.	BioInvent BioInvent focuses on the discovery and development of antibody-based drugs against cancer.	Inventiva Inventiva is a clinical stage biopharmaceutical company with an expertise in fibrosis, oncology and orphan diseases.	Therapeia Therapeia is a company that specializes in the development of diagnostic and therapeutic radiopharmaceuticals for unmet patient needs.	Calviri Calviri is a company that develops diagnostic and therapeutic products, as well as vaccines aimed to prevent cancer.
Founding Date	Founding Date 2003	Founding Date 1997	Founding Date 2011	Founding Date 2007	Founding Date 2018
Type	Type Public	Type Public	Type Public	Type Private	Type Private
Tags	Tags Healthcare biotech drug development medical diagnostics oncology pharma	Tags Healthcare biotech drug development medical diagnostics oncology pharma	Tags Healthcare biotech clinical research drug development medical diagnostics oncology pharma	Tags Healthcare biotech drug development medical diagnostics oncology pharma therapy	Tags Healthcare biotech drug development medical diagnostics oncology pharma
Locations	Locations Oslo, NO HQ	Locations Lund, SE HQ	Locations Daix, FR HQ	Locations Dresden, DE HQ	Locations Phoenix, US HQ
Employees	Employees 215% increase	Employees 118	Employees 114	Employees N/A	Employees 16
Valuation ($)	Valuation ($) 31.4 m	Valuation ($) 285.9 m	Valuation ($) 231 m	Valuation ($) N/A	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) kr226.5m (FY, 2025)	Revenue (est.) €4.5m (FY, 2025)	Revenue (est.) N/A	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit kr226.6m (FY, 2025)	Gross profit €7.9m (FY, 2025)	Gross profit N/A	Gross profit N/A
Net income	Net income (kr60m) (FY, 2025)	Net income (kr332.9m) (FY, 2025)	Net income (€354.1m) (FY, 2025)	Net income N/A	Net income N/A
Funding
Total funding raised	Total funding raised $ 10.4m	Total funding raised N/A	Total funding raised N/A	Total funding raised N/A	Total funding raised $ 2.3m